[af3e0d]: / notebooks / logs / 2025-02-21_application.log

Download this file

53 lines (52 with data), 13.4 kB

{"timestamp": "2025-02-21T10:06:01.823116", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: whitespace_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.823750", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: length_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.824190", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: special_character_cleaner", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.824566", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: medical_score_processor", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.824961", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: medical_abbreviation_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.825354", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: medical_term_standardizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.825807", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: als_preprocessor", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.828286", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: domain_specific_stopword_handler", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.828813", "level": "INFO", "name": "__main__", "module": "2914501069", "function": "add_step", "line": 13, "message": "Added preprocessing step: medical_tokenizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.829296", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 24, "message": "Starting text preprocessing", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.829722", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 25, "message": "Original text: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline; \n               FVC = 65% \u00b1 5%. ALSFRS-R score decreased from 42 to 38 over 3 months. \n               The subject received treatment with 100mg/day medication.", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.830089", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying whitespace_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.830365", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After whitespace_normalizer: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline; FVC = 65% \u00b1 5%. ALSFRS-R score decreased from 42 to 38 over 3 months. The subject received treatment with 100mg/day medication.", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.830603", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.830846", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 237 -> 205", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.831091", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying length_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.831331", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After length_normalizer: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline; FVC = 65% \u00b1 5%. ALSFRS-R score decreased from 42 to 38 over 3 months. The subject received treatment with 100mg/day medication.", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.831556", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.831806", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 205 -> 205", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.832046", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying special_character_cleaner", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.833021", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After special_character_cleaner: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline FVC 65 % \u00b1 5 %. ALSFRS-Rscore decreased from 42 to 38 over 3 months. The subject received treatment with 100 mg100 mg/daymedication . ", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.833256", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.833535", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 205 -> 211", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.833774", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 39, "message": "- Medical terms: ['measurements: 65%', 'measurements: 5%', 'compound_terms: ALSFRS-R', 'measurements: 100mg', 'compound_terms: 100mg/day']", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.833988", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 41, "message": "- Special chars: {'_': 0, ']': 0, '{': 0, '=': 1, '}': 0, '+': 0, '[': 0, '\\\\': 0, '*': 0, ':': 0, ';': 1, '|': 0, ')': 1, '(': 1, '\u00b1': 1, '.': 3}", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.834214", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying medical_score_processor", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.835010", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After medical_score_processor: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline FVC 65 % \u00b1 5 %. ALSFRS-Rscore decreased from 42 to 38 over 3 months. The subject received treatment with 100 mg100 mg/daymedication . ", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.835423", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.835847", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 211 -> 211", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.836095", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying medical_abbreviation_normalizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.836727", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After medical_abbreviation_normalizer: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline Forced Vital Capacity (FVC) 65 % \u00b1 5 %. ALSFRS-Rscore decreased from 42 to 38 over 3 months. The subject received treatment with 100 mg100 mg/daymedication . ", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.836964", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.837232", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 211 -> 235", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.837512", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying medical_term_standardizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.838643", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After medical_term_standardizer: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline Forced Vital Capacity (FVC) 65 % \u00b1 5 %. ALSFRS-Rscore decreased from 42 to 38 over 3 months. The subject received treatment with 100 mg100 mg/daymedication . ", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.838878", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.839109", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 235 -> 235", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.839427", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying als_preprocessor", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.839858", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After als_preprocessor: Patient with ALS (amyotrophic lateral sclerosis) showing respiratory decline Forced Vital Capacity (FVC) 65 % \u00b1 5 %. ALSFRS-Rscore decreased from 42 to 38 over 3 months. The subject received treatment with 100 mg100 mg/daymedication . ", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.840098", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.840404", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 235 -> 235", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.840686", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 39, "message": "- Medical terms: ['amyotrophic lateral sclerosis', 'respiratory']", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.841004", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying domain_specific_stopword_handler", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.841512", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After domain_specific_stopword_handler: ALS (amyotrophic lateral sclerosis) showing respiratory decline Forced Vital Capacity (FVC) 65 % \u00b1 5 %. ALSFRS-Rscore decreased 42 38 3 months. received treatment 100 mg100 mg/daymedication .", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.841821", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.841997", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 235 -> 191", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.842187", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 39, "message": "- Medical terms: ['ALS', '65', '5', '42', '38', '3', 'treatment', '100']", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.842349", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 30, "message": "\nApplying medical_tokenizer", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.843019", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 32, "message": "After medical_tokenizer: ALS (amyotrophic lateral sclerosis) showing respiratory decline F orced V ital C apacity (FVC) 65 % \u00b1 5 %. ALSFR S-R score decreased 42 38 3 months. received treatment 100 mg100 mg/daymedication .", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.843248", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 36, "message": "Step statistics:", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.843664", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 37, "message": "- Length change: 196 -> 196", "taskName": "Task-4"}
{"timestamp": "2025-02-21T10:06:01.843943", "level": "INFO", "name": "__main__", "module": "2835056842", "function": "<module>", "line": 43, "message": "\nPreprocessing complete", "taskName": "Task-4"}